Mycobacterium marinum is a non-tuberculous mycobacterium first isolated from tubercles obtained at necropsy of dead saltwater fish in an aquarium in Philadelphia in 1926. It causes a tuberculosis-like illness in fish. In humans, when injured skin is exposed to an aqueous environment contaminated with M. marinum, infection occurs. This infection presents as a nodular granulomatous disease, which can spread along lymphatics similar to a sporothrix infection. M. marinum is found in plants, soil, and fish. The infections are usually limited to the skin and soft tissues and occur in immunocompetent patients. Disseminated M. marinum infection in patients with HIV/AIDS have infrequently been reported.
M. marinum is a non-motile, non-spore forming, gram-positive, acid-fast bacillus. M. marinum is slow-growing mycobacteria, belonging to group 1 of the Runyon classification. It is a photochromogen and produces a yellow pigment when exposed to light. M. marinum grows best on Lowenstein-Jensen medium at 32 degrees Centigrade (C). Unlike Mycobacterium tuberculosis (MTB), the growth of M. marinum is inhibited at 37 degrees C. Phylogenetically, M. marinum is very closely related to M. ulcerans, and both are closely related to M. tuberculosis based on their 99.3%, 16SrRNA sequence homology. In fact, M. marinum causes tuberculosis-like disease in fish and frogs. Like MTB, M. marinum can survive inside host cells and is proposed as a model to study MTB. Like in MTB infection, M. marinum may cause a positive tuberculin test. M marinum has one rRNA operon per genome, which dictates the pace of mRNA-protein synthesis. Genomic analysis suggests that the rRNA operon is similar in both MTB and M. marinum. Unlike MTB, M. marinum is a rapid grower, so the reason for this difference is unknown. At the infection site, M. marinum has a generation time of 24 hours, similar to MTB, but in the laboratory, at 32 degrees C, the generation time is 4 hours. MTB generation time in the lab is 24 hours when grown at 37 degrees C. There is no one good antibiotic regimen for M. marinum.
The first human case of M. marinum was reported from Sweden in 1951 by Norden and Linell. The mycobacteria were isolated from skin lesions of swimmers who had bathed in a contaminated pool. Nowadays, chlorination to sanitize swimming pools is a routine practice; therefore, swimming is no longer a risk factor for M. marinum infection. Potential risk factors are working in wet fields, participating in aquatic sports or cleaning a fish aquarium at home. The annual incidence of M. marinum infection in the USA is 0.27 cases per 100.000 inhabitants. The two conditions required for M. marinum infection are a presence of injury or abrasion to the skin and exposure to the contaminated aqueous environment. In one study almost half (49%) of M. marinum infections were aquarium related, 27% were related to fish or shellfish injuries, and 9% were related to injuries associated with saltwater or brackish water. Risk factors for individuals with HIV are similar. Disseminated infection can occur in immunocompromised patients.
Patient evaluation should identify the likely exposure of the injured skin to aqueous material contaminated with M. marinum. Skin injury may be in the form of minor abrasions, cuts, or major trauma. Besides the aqueous environment, M. marinum is also found in plants and soil. The most common clinical infections due to M. marinum are skin and soft tissue infections most likely due to its propensity to flourish in the cooler environment. A skin infection may present as a solitary, violaceous or red, plaque or nodule. The nodular surface can be crusted or verrucous. The nodule may appear inflammatory and may have pus. There can be lymphangitic spread in a sporotrichoid presentation. M. marinum should be in the differential diagnosis of poorly healing nodular lesions not responding to antibiotics in the upper extremities. Based upon the exposure to M. marinum, skin lesions can also be present in the lower extremities. M. marinum infections in patient with HIV have been reported in the pre-anti-retroviral therapy (ART) era but are uncommon in the post-ART era. Disseminated infection can occur in non-HIV immunocompromised hosts as well.
Communication with the diagnostic laboratory is essential to make the diagnosis. When M. marinum infection is suspected, the laboratory team will utilize Lowenstein-Jensen agar cultures which can be incubated at 28 to 32 degrees C, in addition to incubating at 37 degrees C. Cultures will need to be observed for six weeks. The positivity rate of cultures ranges from 70% to 80%. Lesions have very low concentration of microorganisms, hence cultures should be obtained even in the absence of microscopic evidence of bacilli. Typical tuberculoid granulomas are seen only in two-thirds of the cases, and the histopathology of nodules can be confused with rheumatoid nodules. One in five nodules may not appear to be of infectious origin in histology. Samples from the deeper parts of the nodule or skin or synovial biopsy may provide information at times, and repeating biopsy can be helpful. M. marinum infections can mimic other histopathological patterns such as a sarcoid-like granuloma or granuloma annulare as well.
Polymerase chain reaction (PCR) amplification techniques using Mycobacterium genus-specific primers can be used to diagnose M. marinum infection directly in the biopsy sample. Ziehl-Neelson stain of biopsy specimens or yellowish discharge is only rarely positive since the number of mycobacteria in clinical specimens is low.
M. marinum infection can also be an opportunistic infection in patients treated with anti-tumor necrosis factor (TNF)-alpha and other biological drugs. Therefore an underlying immunosuppressed state must be excluded upon the diagnosis of M. marinum infection. Tuberculin skin test using purified protein derivative is positive in 67%-100% of cases. Quantiferon-TB Gold and enzyme-linked immunospot assay may also be positive in M. marinum infections but are unhelpful for diagnosis. Positive blood culture findings have also been reported in disseminated infections. Recently in vivo imaging to monitor long-term anti-mycobacterial therapy has been proposed and such diagnostic tools are being developed.
Routine susceptibility testing is not recommended when treating M. marinum infections. There is not much correlation between in vitro susceptibilities and clinical response. The therapy is not standardized. Rifampin is the most active drug against M. marinum with MIC90 of < 0.5mg/mL. In one study, the MIC for ethambutol was 2.0 mg/mL to 4.0 mg/mL, for doxycycline was 16.0 mg/mL, for imipenem was 8.0 mg/mL, and for INH was 8.0 mg/mL. M. marinum is intrinsically resistant to pyrazinamide. M. marinum has moderately high MIC90 for ciprofloxacin and levofloxacin but is susceptible to moxifloxacin (MIC90) of 1 mg/mL - 2 mg/ml). Linezolid has activity against M. marinum as well. Clinically clarithromycin-based regimens have had a good success rate irrespective of the in vitro MIC values.
There is no consensus on the regimen or the duration of therapy in M. marinum infections. A spectrum of antibiotic regimens has been used in published cases or case series. There are no randomized controlled trials. Minocycline monotherapy in immunocompetent patients has been used. Generally, combination therapy for immunosuppressed patients is used. Consider treatment with a chosen regimen for three months prior to changing the antibiotic therapy as the response to therapy is slow. Surgical debridement is often needed. Effective antibiotic therapy is usually associated with healing of all skin lesions within one month of commencing therapy. After that, immunocompetent patients should continue the medications for two more months. Patients who are immunocompromised will need to be treated with two agents for at least six months. In one report, a patient with AIDS was successfully treated with rifampin and ethambutol for six months. The lesion recurred after stopping therapy, so therapy was restarted with a clarithromycin regimen. Sometimes chronic lifelong suppressive therapy may be needed.
Based on the available evidence, it seems prudent to treat immunocompromised hosts with M. marinum infection with two agents, including clarithromycin. The optimal duration of therapy in the setting of the immunocompromised host is unknown. Most experts would treat for six months and possibly lifelong in cases of a persistent immunocompromised state. Disseminated disease is treated for a duration of one year in published case reports. Rifampin and ethambutol were frequently used in invasive M. marinum infections. In a study of 61 clinical isolates, rifamycins and clarithromycin were the most potent against M. marinum.
Cutaneous nodular infections, especially fungal and granulomatous infections, are in the differential. These include:
Other cutaneous lymphatic infections that might have a similar presentation include:
In most cases, especially in patients with immunocompetent status, M marinum infection with treatment carries an excellent prognosis. Treatment failure may result due to deeper-structure involvement and ulcerative skin lesions. There is a very low risk of antimicrobial resistance. Clinical outcomes of M marinum infections in patients with HIV infection do not differ from those without HIV infections. A continued immunocompromised state and ongoing risk of exposure can increase the risk of disease. Some patients may need lifelong suppression therapy.
Chronic complications of the disease are minimal with early diagnosis and adequate treatment. Some patients may develop persistent ulceration at the site of initial exposure. With delayed treatment or improper selection/duration of antibiotic therapy, patients may develop deeper infections, including osteomyelitis, tenosynovitis, and disseminated disease, which may require amputation of involved tissue.
Once a diagnosis of M marinum infection is made, it is important to instruct the patient on limiting his/her risks of exposure to the bacterium. The patients themselves are not infectious to other individuals, which is of most concern to patients and family members. Avoiding contact with aquatic environments when skin abrasions/cuts are present is ideal. When exposure cannot be avoided, such as in the case of individuals who work near saltwater, they should be instructed on proper cleansing of the skin after water exposure with an antibacterial preparation and to cover abrasions with waterproof bandages. Individuals who work with aquariums should wear gloves at all times.
Surgical debridement is frequently necessary and should be included in the management plan. Antibiotic therapy is still needed after surgical debridement.
Mycobacterium marinum infections are on the rise as more people take to water activities. The infection is not easy to diagnose and its management can be difficult in some cases. The infection predominantly affects the extremities and is best managed by an interprofessional team that includes clinicians, nurses, and pharmacists to help optimize clinical outcomes. The clinician needs to maintain a high degree of suspicion for the disease in patients with exposure to aquatic environments to help diagnose the condition early and accurately. The clinician must communicate with the clinical laboratory technicians and pathologists to ensure appropriate culture mediums and the correct duration of observation is set. The specialized wound care nurse plays a vital in assisting the medical team with the treatment of the disease. The nurse helps educate the patient on proper wound care to ensure wound healing and decreasing the risk of superimposed infections. The pharmacists help assist the medical team by educating the patient on potential side-effects of therapy as well as the need for compliance with the long duration of therapy. The pharmacist can help identify adverse reactions and decreased compliance with therapy as well as recommending the optimal treatment regimen for the patient based on their individual comorbidities. A collaborative interprofessional team can help decrease patient morbidity and mortality with this disease.
|||Streit M,Böhlen LM,Hunziker T,Zimmerli S,Tscharner GG,Nievergelt H,Bodmer T,Braathen LR, Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. European journal of dermatology : EJD. 2006 Jan-Feb; [PubMed PMID: 16436349]|
|||Ackleh AS,Delcambre ML,Sutton KL, A second-order high-resolution finite difference scheme for a size-structured model for the spread of Mycobacterium marinum. Journal of biological dynamics. 2015; [PubMed PMID: 25271885]|
|||Parent LJ,Salam MM,Appelbaum PC,Dossett JH, Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1995 Nov; [PubMed PMID: 8589169]|
|||Chen L,Liu Z,Su Y,Wang D,Yin B,Shu B,Zhang J,Zhu X,Jia C, Characterization of Mycobacterium marinum infections in zebrafish wounds and sinus tracts. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017 May; [PubMed PMID: 28466489]|
|||Prouty MG,Correa NE,Barker LP,Jagadeeswaran P,Klose KE, Zebrafish-Mycobacterium marinum model for mycobacterial pathogenesis. FEMS microbiology letters. 2003 Aug 29; [PubMed PMID: 12951238]|
|||Hashish E,Merwad A,Elgaml S,Amer A,Kamal H,Elsadek A,Marei A,Sitohy M, Mycobacterium marinum infection in fish and man: epidemiology, pathophysiology and management; a review. The Veterinary quarterly. 2018 Dec [PubMed PMID: 29493404]|
|||Jernigan JA,Farr BM, Incubation period and sources of exposure for cutaneous Mycobacterium marinum infection: case report and review of the literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000 Aug [PubMed PMID: 10987702]|
|||Aubry A,Mougari F,Reibel F,Cambau E, Mycobacterium marinum. Microbiology spectrum. 2017 Apr [PubMed PMID: 28387180]|
|||Seneviratne K,Herieka E, A rifampicin-resistant Mycobacterium marinum infection in a newly diagnosed HIV-1 individual. International journal of STD & AIDS. 2013 Jan [PubMed PMID: 23512514]|
|||Primm TP,Lucero CA,Falkinham JO 3rd, Health impacts of environmental mycobacteria. Clinical microbiology reviews. 2004 Jan [PubMed PMID: 14726457]|
|||Hosseini Fard SM,Yossefi MR,Esfandiari B,Sefidgar SA, Mycobacterium marinum as a cause of skin chronic granulomatous in the hand. Caspian journal of internal medicine. 2011 Winter [PubMed PMID: 24024015]|
|||Ang P,Rattana-Apiromyakij N,Goh CL, Retrospective study of Mycobacterium marinum skin infections. International journal of dermatology. 2000 May [PubMed PMID: 10849123]|
|||Posteraro B,Sanguinetti M,Garcovich A,Ardito F,Zampetti A,Masucci L,Sbordoni G,Cerimele D,Fadda G, Polymerase chain reaction-reverse cross-blot hybridization assay in the diagnosis of sporotrichoid Mycobacterium marinum infection. The British journal of dermatology. 1998 Nov [PubMed PMID: 9892957]|
|||López-Varela E,García-Basteiro AL,Santiago B,Wagner D,van Ingen J,Kampmann B, Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis. The Lancet. Respiratory medicine. 2015 Mar [PubMed PMID: 25773213]|
|||Winthrop KL,Yamashita S,Beekmann SE,Polgreen PM, Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Jun 1 [PubMed PMID: 18419421]|
|||Schliemann S,Rässler F,Tittelbach J,Kranzer K,Zollmann C,Elsner P, Disseminated Mycobacterium marinum skin infection due to chronic lymphedema in an immunocompetent patient. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018 May [PubMed PMID: 29603601]|
|||Tenbrick P,Beer M,Beer K, Treatment of biopsy and culture negative Mycobacterium marinum: diagnostic and therapeutic considerations. Journal of drugs in dermatology : JDD. 2014 Feb [PubMed PMID: 24509973]|
|||Bråbäck M,Riesbeck K,Forsgren A, Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrobial agents and chemotherapy. 2002 Apr [PubMed PMID: 11897601]|
|||Bonnet E,Debat-Zoguereh D,Petit N,Ravaux I,Gallais H, Clarithromycin: a potent agent against infections due to Mycobacterium marinum. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1994 Apr [PubMed PMID: 8038339]|
|||Aubry A,Chosidow O,Caumes E,Robert J,Cambau E, Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Archives of internal medicine. 2002 Aug 12-26 [PubMed PMID: 12153378]|
|||Chow SP,Ip FK,Lau JH,Collins RJ,Luk KD,So YC,Pun WK, Mycobacterium marinum infection of the hand and wrist. Results of conservative treatment in twenty-four cases. The Journal of bone and joint surgery. American volume. 1987 Oct [PubMed PMID: 3667646]|